Protease Inhibitor

A protease inhibitor is a chemical or biological compound that blocks the enzymatic activity of proteases — enzymes capable of cleaving peptide bonds. In peptide research, these inhibitors play two key roles: preserving the integrity of studied peptides against contaminating or endogenous proteases, and serving as research objects for specific biological pathways.

Several classes exist by mechanism. (1) Serine protease inhibitors: PMSF, aprotinin, leupeptin (target trypsin, chymotrypsin, plasmin, thrombin). (2) Cysteine protease inhibitors: E-64, iodoacetamide (target papain, caspases, cathepsins). (3) Metalloprotease inhibitors: EDTA, EGTA, 1,10-phenanthroline (chelate Zn²⁺, Ca²⁺, block MMPs, ACE, neprilysin). (4) Aspartyl protease inhibitors: pepstatin A (target pepsin, renin, BACE-1).

In laboratory use, commercial cocktails (Complete Protease Inhibitor, Halt) combine 4 to 7 inhibitors covering the full spectrum. They are systematically added to cell lysates, tissue homogenates and purification buffers to prevent artifactual proteolysis of target peptides during extraction.

For research peptides themselves in solution, proteolytic contamination is usually negligible in sterile conditions, but certain in vitro protocols (serum incubation, cell culture) require inhibitor addition to measure "pure" activity independent of proteolytic turnover.

Finally, certain catalog molecules may themselves act as selective inhibitors in targeted research contexts (DPP-4, ACE, neprilysin, MMP studies), opening varied experimental paths. All handling remains strictly RUO: these inhibitors are bench tools, not substances for human use.

Protease inhibitors are classified by the catalytic mechanism they block: serine protease inhibitors (PMSF irreversible, AEBSF more stable in solution, aprotinin reversible broad-spectrum, chymostatin), cysteine protease inhibitors (E-64 targeting papain and cathepsins, leupeptin broad-spectrum), metalloprotease inhibitors (EDTA Zn²⁺/Ca²⁺ chelator, 1,10-phenanthroline, phosphoramidon), aspartyl protease inhibitors (pepstatin A targeting pepsin, renin, cathepsin D).

In RUO peptide research these inhibitors serve several purposes: (1) preserve peptides in cell lysates or biological samples during pharmacokinetic quantification, (2) stabilise target enzymes during in vitro activity tests, (3) study specific metabolic pathways by selectively blocking an enzymatic class. Commercial cocktails (Roche cOmplete, Sigma P8340) combine 4-7 inhibitors for broad spectrum. Some therapeutic peptides are themselves endogenous inhibitors (e.g., Ac-SDKP prolyl oligopeptidase inhibitor, BPP-9a ACE inhibitor at the origin of captopril). Inhibition measurement is done by Michaelis-Menten kinetic assay (IC50, Ki, Km) with fluorogenic or chromogenic substrate.